Browse by Person

Export as [feed] Atom [feed] RSS
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 7.

Article

Urbonas, V., Schadendorf, D., Zimmer, L. et al. (11 more authors) (2019) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology, 30 (2). pp. 317-324. ISSN 0923-7534

Corrie, P.G., Marshall, A., Nathan, P.D. et al. (36 more authors) (2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8). pp. 1843-1852.

Graziano, J., Cooper, T. and Marshall, E. orcid.org/0000-0001-8883-4859 (2017) Book reviews : New York City and the Hollywood Musical: Dancing in the Streets, Martha Shearer (2016), London: Palgrave Macmillan, 230 pp., ISBN: 9781137569370, h/bk, £67.99. Studies in Musical Theatre, 11 (3). pp. 311-318. ISSN 1750-3159

Turner, H., Marshall, E., Wood, F. et al. (2 more authors) (2016) CBT for eating disorders: The impact of early changes in eating pathology on later changes in personality pathology, anxiety and depression. Behaviour Research and Therapy, 77. 1 - 6. ISSN 0005-7967

Baird, R., Banks, I., Cameron, D. et al. (53 more authors) (2016) An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 10. p. 608.

Turner, H., Marshall, E., Stopa, L. et al. (1 more author) (2015) Cognitive-behavioural therapy for outpatients with eating disorders: Effectiveness for a transdiagnostic group in a routine clinical setting. Behaviour Research and Therapy, 68. 70 - 75.

Corrie, P., Marshall, A., Dunn, J. et al. (17 more authors) (2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, 15 (6). pp. 620-630. ISSN 1470-2045

This list was generated on Sat Jan 1 18:13:39 2022 GMT.